Envestnet Portfolio Solutions Inc. increased its holdings in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 2.3% during ...

Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.

Insulet (PODD) on Tuesday priced a private placement of $450M aggregate principal amount of senior unsecured notes due 2033, for net proceeds of about $444.4M.

Insulet (NASDAQ:PODD – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Tuesday. Several other equities analysts ...

Following the announcement on March 18, PODD’s shares climbed 2% to $265.82 in Tuesday’s trading session. The company’s solid innovation efforts and ongoing expansion of the Omnipod 5 ...

Shares of Insulet Corp. PODD slid 5.93% to $266.68 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.37% ...

Below is Validea's guru fundamental report for INSULET CORP (PODD). Of the 22 guru strategies we follow, PODD rates highest using our Twin Momentum Investor model based on the published strategy ...

Click here to discover the nuances of Insulet with our detailed analytical report. NasdaqGS:PODD Revenue & Expenses Breakdown as at Mar 2025 Insulet (NasdaqGS:PODD) has rewarded its shareholders ...